State Street’s Kura Oncology KURA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $58.5M | Buy |
5,329,208
+817,317
| +18% | +$7.71M | ﹤0.01% | 1755 |
|
|
2026
Q1 | $36.7M | Sell |
4,511,891
-419,199
| -9% | -$3.6M | ﹤0.01% | 1915 |
|
|
2025
Q4 | $51.2M | Buy |
4,931,090
+1,587,959
| +47% | +$16.7M | ﹤0.01% | 1729 |
|
|
2025
Q3 | $29.6M | Buy |
3,343,131
+306,273
| +10% | +$2.18M | ﹤0.01% | 2023 |
|
|
2025
Q2 | $17.5M | Sell |
3,036,858
-245,222
| -7% | -$1.5M | ﹤0.01% | 2261 |
|
|
2025
Q1 | $21.7M | Sell |
3,282,080
-63,382
| -2% | -$494K | ﹤0.01% | 2097 |
|
|
2024
Q4 | $29.1M | Buy |
3,345,462
+676,618
| +25% | +$9.74M | ﹤0.01% | 2003 |
|
|
2024
Q3 | $52.1M | Sell |
2,668,844
-215,697
| -7% | -$4.37M | ﹤0.01% | 1691 |
|
|
2024
Q2 | $59.4M | Sell |
2,884,541
-1,315,413
| -31% | -$27M | ﹤0.01% | 1577 |
|
|
2024
Q1 | $89.6M | Buy |
4,199,954
+1,278,144
| +44% | +$24.8M | ﹤0.01% | 1378 |
|
|
2023
Q4 | $42M | Sell |
2,921,810
-334,777
| -10% | -$3.29M | ﹤0.01% | 1794 |
|
|
2023
Q3 | $29.7M | Buy |
3,256,587
+243,439
| +8% | +$2.47M | ﹤0.01% | 1926 |
|
|
2023
Q2 | $31.9M | Sell |
3,013,148
-829,530
| -22% | -$9.81M | ﹤0.01% | 1946 |
|
|
2023
Q1 | $47M | Sell |
3,842,678
-603,749
| -14% | -$7.53M | ﹤0.01% | 1690 |
|
|
2022
Q4 | $55.2M | Buy |
4,446,427
+77,664
| +2% | +$1.13M | ﹤0.01% | 1559 |
|
|
2022
Q3 | $59.7M | Buy |
4,368,763
+1,337,149
| +44% | +$20.6M | ﹤0.01% | 1474 |
|
|
2022
Q2 | $55.6M | Sell |
3,031,614
-269,134
| -8% | -$3.87M | ﹤0.01% | 1564 |
|
|
2022
Q1 | $53.1M | Sell |
3,300,748
-77,395
| -2% | -$1.12M | ﹤0.01% | 1721 |
|
|
2021
Q4 | $47.3M | Buy |
3,378,143
+169,034
| +5% | +$2.74M | ﹤0.01% | 1840 |
|
|
2021
Q3 | $60.1M | Sell |
3,209,109
-45,533
| -1% | -$858K | ﹤0.01% | 1669 |
|
|
2021
Q2 | $67.9M | Buy |
3,254,642
+420,992
| +15% | +$10.5M | ﹤0.01% | 1617 |
|
|
2021
Q1 | $80.1M | Buy |
2,833,650
+156,430
| +6% | +$4.95M | ﹤0.01% | 1404 |
|
|
2020
Q4 | $87.4M | Buy |
2,677,220
+946,021
| +55% | +$33.2M | 0.01% | 1251 |
|
|
2020
Q3 | $53M | Buy |
1,731,199
+77,498
| +5% | +$1.71M | ﹤0.01% | 1422 |
|
|
2020
Q2 | $27M | Buy |
1,653,701
+569,974
| +53% | +$8.22M | ﹤0.01% | 1859 |
|
|
2020
Q1 | $10.8M | Buy |
1,083,727
+23,444
| +2% | +$268K | ﹤0.01% | 2234 |
|
|
2019
Q4 | $14.6M | Sell |
1,060,283
-166,245
| -14% | -$2.46M | ﹤0.01% | 2337 |
|
|
2019
Q3 | $18.6M | Buy |
1,226,528
+419,582
| +52% | +$7.47M | ﹤0.01% | 2102 |
|
|
2019
Q2 | $15.9M | Sell |
806,946
-136,891
| -15% | -$2.27M | ﹤0.01% | 2253 |
|
|
2019
Q1 | $15.7M | Buy |
943,837
+70,211
| +8% | +$1.08M | ﹤0.01% | 2208 |
|
|
2018
Q4 | $12.3M | Sell |
873,626
-296,720
| -25% | -$3.93M | ﹤0.01% | 2318 |
|
|
2018
Q3 | $20.5M | Buy |
1,170,346
+135,165
| +13% | +$2.59M | ﹤0.01% | 2158 |
|
|
2018
Q2 | $18.8M | Buy |
1,035,181
+256,297
| +33% | +$4.34M | ﹤0.01% | 2167 |
|
|
2018
Q1 | $14.6M | Buy |
778,884
+490,758
| +170% | +$9.55M | ﹤0.01% | 2259 |
|
|
2017
Q4 | $4.41M | Buy |
288,126
+46,248
| +19% | +$682K | ﹤0.01% | 2846 |
|
|
2017
Q3 | $3.61M | Buy |
241,878
+92,129
| +62% | +$865K | ﹤0.01% | 2944 |
|
|
2017
Q2 | $1.39M | Buy |
+149,749
| New | +$1.36M | ﹤0.01% | 3260 |
|
Other funds holding KURA
SCM
BI
AC
ACM
PM
State Street's KURA Position: Q2 2026 in Review
State Street increased its Kura Oncology (KURA) stake by 18% in Q2 2026, buying an estimated $7.71M and bringing the position to 5,329,208 shares worth $58.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1755.
State Street first reported a position in KURA in Q2 2017 and has held it in 37 quarters since. The position peaked at $89.6M in Q1 2024. 220 funds tracked by Wall St. Rank hold KURA as of Q2 2026.
- State Street held 5,329,208 shares of Kura Oncology worth $58.5M as of Q2 2026.
- State Street bought 817,317 Kura Oncology shares in Q2 2026, an estimated $7.71M.
- Kura Oncology made up ﹤0.01% of State Street's portfolio in Q2 2026, its #1755 holding.
- State Street first reported a position in Kura Oncology in Q2 2017 and has held it in 37 quarters since.
- State Street's Kura Oncology position peaked at $89.6M in Q1 2024.
- 220 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.
Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.